Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Assets (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Current Assets for 12 consecutive years, with $149.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets rose 20.16% year-over-year to $149.2 million, compared with a TTM value of $149.2 million through Sep 2025, up 20.16%, and an annual FY2024 reading of $107.3 million, down 41.34% over the prior year.
  • Current Assets was $149.2 million for Q3 2025 at CytomX Therapeutics, down from $164.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $400.0 million in Q1 2021 and bottomed at $86.6 million in Q1 2025.
  • Average Current Assets over 5 years is $204.6 million, with a median of $200.3 million recorded in 2022.
  • Peak annual rise in Current Assets hit 20.16% in 2025, while the deepest fall reached 48.2% in 2025.
  • Year by year, Current Assets stood at $310.3 million in 2021, then decreased by 23.59% to $237.1 million in 2022, then decreased by 22.85% to $182.9 million in 2023, then tumbled by 41.34% to $107.3 million in 2024, then surged by 39.06% to $149.2 million in 2025.
  • Business Quant data shows Current Assets for CTMX at $149.2 million in Q3 2025, $164.6 million in Q2 2025, and $86.6 million in Q1 2025.